Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001922321 | SCV002150944 | uncertain significance | Pityriasis rubra pilaris; Psoriasis 2 | 2022-07-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 1382856). This variant has not been reported in the literature in individuals affected with CARD14-related conditions. This variant is present in population databases (rs533044405, gnomAD 0.02%). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 438 of the CARD14 protein (p.Cys438Tyr). |
Ambry Genetics | RCV004603056 | SCV005102727 | uncertain significance | Inborn genetic diseases | 2024-03-25 | criteria provided, single submitter | clinical testing | The c.1313G>A (p.C438Y) alteration is located in exon 9 (coding exon 8) of the CARD14 gene. This alteration results from a G to A substitution at nucleotide position 1313, causing the cysteine (C) at amino acid position 438 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |